Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter ended on June 30, 202210-08-2022
10-08-2022
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Approval Of The Unaudited Financial Results For The Quarter Ended On June 30, 2022
Approval of the unaudited financial results for the quarter ended on June 30, 202210-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We wish to inform that the USFDA conducted an inspection of our Moraiya manufacturing facility located at Ahmedabad from 26th July to 5th August, 2022. The inspection concluded with four Form 483 observations. None of the observations were related to data integrity. The Company will address the observations within the stipulated timeline.05-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst meet scheduled at 4.30 p.m. on Wednesday, August 10, 202205-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press releases dated August 4, 2022 titled 'Zydus receives final approval from the USFDA for Ivermectin Cream' and 'Zydus receives final approval from the USFDA for Empagliflozin Tablets'.04-08-2022
Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for To Approve Unaudited Financial Results For The Quarter Ended On June 30, 2022
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 ,inter alia, to consider and approve unaudited financial results for the quarter ended on June 30, 202203-08-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Revised Disclosures under SEBI (PIT) Regulations, 201527-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated July 26, 2022 titled 'Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets'.26-07-2022
Zydus Lifesciences Ltd - 532321 - Extinguishment Of Equity Shares
Extinguishment of equity shares pursuant to buyback22-07-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection21-07-2022